Author name: lhasalimited

“As Adverse Outcome Pathways (AOPs) move from being an interesting scientific concept, to a useful practical application tool, this is an exciting time for both industry and Lhasa” … Regular Lhasa blog readers will have read this statement within our September blog “Shaping Lhasa Limited’s scientific direction through collaboration”. It is with great excitement that

It is common knowledge to those submitting drug substances for regulatory assessment, that an in silico assessment of mutagenic potential may be conducted in lieu of carcinogenicity or bacterial mutagenicity data for any impurities. A key requirement in ICH M7 states that “Two (Q)SAR prediction methodologies that complement each other should be applied. One methodology

“Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators” At Lhasa Limited we often talk about the importance of industry involvement in shaping our direction. This involvement and collaboration takes places across many areas – perhaps most notably in recent years within the Mirabilis and Effiris consortia, where at

In this blog piece, we explore how Derek Nexus, our expert, knowledge-based toxicology software, performs against 7 alternative in silico skin sensitisation models. Providing qualitative predictions for many toxicity endpoints, including assessment of skin sensitisation, Derek can predict quantitative EC3 predictions for skin sensitisation as well as negative predictions for those query compounds which do

Written by Alison Reeves with top tips by Diego Gomes. Many readers of this blog will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. N-nitrosamines are compounds characterised by a nitroso group bonded to an amine group – nitrosamines are of concern as they can be mutagenic,

In a recent webinar on the Lhasa Carcinogenicity Database (LCDB), Lhasa Limited Senior Scientist, Andrew Thresher, Principal Business Analyst, Simon Gayton, and Principal Global Alliance Manager, Will Drewe, gave an overview, a demonstration and a discussion of the recent LCDB release features. In this blog piece, we explore in more detail, the features of the recent release and how they will

Written by Alison Reeves with top tips by Fernanda Waechter. Many readers of this blog will be aware of the threat posed by potentially mutagenic impurities within drug substance synthesis. Such impurities often arise from reagents which are critical to the synthesis therefore this impurity-related threat is unavoidable. As such, there is a need to assess